Skip to main content
Caplight Logo









NeuroSigma

NeuroSigma

Private
Los Angeles, CaliforniaHealthcare & Life Scienceshttps://www.neurosigma.com/

Last Round

Corporate Funding

Dec 15, 2025

Total Funding Raised

$9.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

NeuroSigma is a bioelectronic medical device company that develops and commercializes non-invasive trigeminal nerve stimulation (TNS) technologies for treating disorders such as pediatric ADHD, epilepsy, and depression.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Mental Health

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales

AI Layer

Non-AI

Keywords

neuromodulationtrigeminal nerve stimulationeTNSbioelectronic medicinenon-invasive medical deviceADHD treatmentnon-pharmacological therapydigital therapeuticspediatric ADHDmedical device consumableshome-based treatmentbrain stimulationneurotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeuroSigma Comparables

Compare NeuroSigma with similar companies based on industry and business-model similarity.

NeuroSigma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neurolief
77%
electroCore
73%
Sooma
72%

NeuroSigma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingDec 15, 2025
Debt ConversionDec 8, 2021
Corporate FundingDec 8, 2021
Corporate FundingSep 21, 2020
GrantFeb 4, 2013

NeuroSigma Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2026

    Monthly visitors grew 115% MoM, reaching 4K.

  • Dec 15, 2025

    $1M raised in corporate funding.

Recent news

Latest coverage and updates

  • launchesJul 21, 2026

    NeuroSigma, Inc. launched eTNS System on Jul 21st '26.

NeuroSigma Filings

Explore SEC and related filing metadata, where available.

NeuroSigma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NeuroSigma's valuation, stock price, and market status.

Is NeuroSigma a public or private company?

NeuroSigma is a private company.

What is the current stock price of NeuroSigma?

NeuroSigma is a private company with no public stock price. No recent secondary market data is available.

How much is NeuroSigma worth (valuation)?

Valuation information for NeuroSigma is not publicly available.

Can I buy NeuroSigma stock?

NeuroSigma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NeuroSigma's last funding round?

NeuroSigma's most recent funding round was Corporate Funding on December 15, 2025.

Who are the main investors in NeuroSigma?

Key investors in NeuroSigma include KT Corporation, Checkmate Capital, National Institute of Neurological Disorders and Stroke.

Will NeuroSigma IPO soon?

No public IPO plans have been announced for NeuroSigma.

How can I track NeuroSigma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NeuroSigma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLos Angeles, California
Employee Range3
Year Founded2008
Last FundingDec 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?